首页|青蒿素及其衍生物治疗结直肠癌的研究进展

青蒿素及其衍生物治疗结直肠癌的研究进展

扫码查看
结直肠癌被认为是全球最常见的恶性肿瘤之一,其发病率和病死率在所有癌症中分别位居第三位和第二位.青蒿素是我国自行研制出的抗疟药物,目前关于青蒿素抗癌特性的研究数据迅速增加.本文综述了青蒿素及其衍生物(artemisinin and its derivatives,ARTs)作为抗癌药物在治疗结直肠癌的机制研究、临床试验以及与其他方法联合治疗等方面的研究进展,希望为未来针对ARTs治疗结直肠癌提供理论依据.
Research progress in the study of artemisinin and its derivatives in the treatment of colorectal cancer
Colorectal cancer is considered one of the most common malignancies worldwide,with the third highest incidence and second highest mortality rates among all cancers.Artemisinin is a self-developed antimalarial drug in China.At present,data on the anticancer effects of artemisinin are accumulating quickly.This review examined how artemisinin and its derivatives(ARTs)worked as anticancer medications to treat colorectal cancer through mechanistic studies,clinical trials,and research advances.It is planned to offer a theory for colorectal cancer treatment using ARTs in the future.

artemisinincolorectal cancercell cyclecell apoptosis

栾诗佳、范翔、王洁、黄菊、马宁、高旭、韩冬

展开 >

哈尔滨医科大学基础医学院生物化学与分子生物学教研室,哈尔滨 150081

青蒿素 结直肠癌 细胞周期 细胞凋亡

黑龙江省自然科学基金联合引导项目国家自然科学基金中国博士后科学基金哈尔滨医科大学第二附属医院创新科研基金

LH2021H057820025062019M661301KYCX2019-01

2023

生命的化学
中国生物化学与分子生物学会

生命的化学

CSTPCD
影响因子:0.404
ISSN:1000-1336
年,卷(期):2023.43(2)
  • 4